Literature DB >> 24871821

Risk for complications in patients with hemophagocytic lymphohistiocytosis who undergo hematopoietic stem cell transplantation: myeloablative versus reduced-intensity conditioning regimens.

Tal Schechter1, Ahmed Naqvi, Sheila Weitzman.   

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative option for patients with primary hemophagocytic lymphohistiocytosis (HLH) and for patients with secondary HLH who fail to respond to therapy. Advances in HSCT and supportive care measures have resulted in improved patient outcomes and decreased treatment-related mortality. Despite the overall improvement in outcome, HLH patients who undergo HSCT using myeloablative conditioning regimens are still at significant risk for complications. The HLH-94 study conducted by the Histiocyte Society reported a 30% TRM with increased pulmonary and hepatic complications. Recently, the use of reduced-intensity conditioning (RIC) regimens has shown favorable outcomes when compared to conventional HSCT and lower rate of acute complications. In this review we compare the potential complications of myeloablative and RIC regimens for HSCT in HLH patients.

Entities:  

Keywords:  BMT; children; complications; hemophagocytic lymphohistiocytosis

Mesh:

Substances:

Year:  2014        PMID: 24871821     DOI: 10.1586/1744666X.2014.920234

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  2 in total

1.  Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates.

Authors:  Matt S Zinter; A Birgitta Versluys; Caroline A Lindemans; Madeline Y Mayday; Gustavo Reyes; Sara Sunshine; Marilynn Chan; Elizabeth K Fiorino; Maria Cancio; Sabine Prevaes; Marina Sirota; Michael A Matthay; Sandhya Kharbanda; Christopher C Dvorak; Jaap J Boelens; Joseph L DeRisi
Journal:  Sci Transl Med       Date:  2022-03-09       Impact factor: 19.319

2.  [Research progress of lymphoma associated hemophagocytic syndrome].

Authors:  X Q Zheng; H Y Zhu; J Y Wang; Lei Fan; Wei Xu; Jianyong Li
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.